Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 60

1.

Lorazepam vs diazepam for pediatric status epilepticus: a randomized clinical trial.

Chamberlain JM, Okada P, Holsti M, Mahajan P, Brown KM, Vance C, Gonzalez V, Lichenstein R, Stanley R, Brousseau DC, Grubenhoff J, Zemek R, Johnson DW, Clemons TE, Baren J; Pediatric Emergency Care Applied Research Network (PECARN).

JAMA. 2014 Apr 23-30;311(16):1652-60. doi: 10.1001/jama.2014.2625.

PMID:
24756515
2.

Systematic review of transition from adolescent to adult care in patients with sickle cell disease.

Jordan L, Swerdlow P, Coates TD.

J Pediatr Hematol Oncol. 2013 Apr;35(3):165-9. doi: 10.1097/MPH.0b013e3182847483. Review.

PMID:
23511487
3.

Hypogonadism in patients with sickle cell disease: central or peripheral?

Taddesse A, Woldie IL, Khana P, Swerdlow PS, Chu JW, Abrams J, Abou-Samra AB.

Acta Haematol. 2012;128(2):65-8. doi: 10.1159/000337344. Epub 2012 Jun 6.

4.

Thalidomide and its analogs for hemoglobinopathies: two birds with one stone?

Kutlar A, Meiler S, Swerdlow P, Knight R.

Expert Rev Hematol. 2012 Feb;5(1):9-11. doi: 10.1586/ehm.11.77. No abstract available.

PMID:
22272699
5.

Inpatient management of sickle cell pain: a 'snapshot' of current practice.

Miller ST, Kim HY, Weiner D, Wager CG, Gallagher D, Styles L, Dampier CD; Investigators of the Sickle Cell Disease Clinical Research Network (SCDCRN).

Am J Hematol. 2012 Mar;87(3):333-6. doi: 10.1002/ajh.22265. Epub 2012 Jan 9.

6.

Clinical trial implementation and recruitment: lessons learned from the early closure of a randomized clinical trial.

Peters-Lawrence MH, Bell MC, Hsu LL, Osunkwo I, Seaman P, Blackwood M, Guillaume E, Bellevue R, Krishnamurti L, Smith WR, Dampier CD, Minniti CP; Sickle Cell Disease Clinical Research Network (SCDCRN).

Contemp Clin Trials. 2012 Mar;33(2):291-7. doi: 10.1016/j.cct.2011.11.018. Epub 2011 Dec 2.

7.

Pomalidomide augments fetal hemoglobin production without the myelosuppressive effects of hydroxyurea in transgenic sickle cell mice.

Meiler SE, Wade M, Kutlar F, Yerigenahally SD, Xue Y, Moutouh-de Parseval LA, Corral LG, Swerdlow PS, Kutlar A.

Blood. 2011 Jul 28;118(4):1109-12. doi: 10.1182/blood-2010-11-319137. Epub 2011 May 2.

8.

The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients.

Smith WR, Ballas SK, McCarthy WF, Bauserman RL, Swerdlow PS, Steinberg MH, Waclawiw MA; Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Pain Med. 2011 May;12(5):697-705. doi: 10.1111/j.1526-4637.2011.01096.x. Epub 2011 Apr 11.

PMID:
21481164
9.

Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease: a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043).

Ataga KI, Reid M, Ballas SK, Yasin Z, Bigelow C, James LS, Smith WR, Galacteros F, Kutlar A, Hull JH, Stocker JW; ICA-17043-10 Study Investigators.

Br J Haematol. 2011 Apr;153(1):92-104. doi: 10.1111/j.1365-2141.2010.08520.x. Epub 2011 Feb 17.

PMID:
21323872
10.

Beneficial effects of nitric oxide breathing in adult patients with sickle cell crisis.

Head CA, Swerdlow P, McDade WA, Joshi RM, Ikuta T, Cooper ML, Eckman JR.

Am J Hematol. 2010 Oct;85(10):800-2. doi: 10.1002/ajh.21832.

11.

Transfusion and chelation practices in sickle cell disease: a regional perspective.

Vichinsky EP, Ohene-Frempong K, Thein SL, Lobo CL, Inati A, Thompson AA, Smith-Whitley K, Kwiatkowski JL, Swerdlow PS, Porter JB, Marks PW.

Pediatr Hematol Oncol. 2011 Mar;28(2):124-33. doi: 10.3109/08880018.2010.505506. Epub 2010 Jul 30.

PMID:
20673030
12.

Approaches to transfusion therapy and iron overload in patients with sickle cell disease: results of an international survey.

Vichinsky EP, Ohene-Frempong K; Transfusion Committee.

Pediatr Hematol Oncol. 2011 Feb;28(1):37-42. doi: 10.3109/08880018.2010.505497. Epub 2010 Jul 30.

PMID:
20673029
13.

The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up.

Steinberg MH, McCarthy WF, Castro O, Ballas SK, Armstrong FD, Smith W, Ataga K, Swerdlow P, Kutlar A, DeCastro L, Waclawiw MA; Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia and MSH Patients' Follow-Up.

Am J Hematol. 2010 Jun;85(6):403-8. doi: 10.1002/ajh.21699.

14.

Sticky platelet syndrome: an unusual presentation of arterial ischemia.

Bojalian MO, Akingba AG, Andersen JC, Swerdlow PS, Bove PG, Brown OW, Rubin JR.

Ann Vasc Surg. 2010 Jul;24(5):691.e1-6. doi: 10.1016/j.avsg.2009.12.005. Epub 2010 Apr 2.

PMID:
20363102
15.

Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies.

Barst RJ, Mubarak KK, Machado RF, Ataga KI, Benza RL, Castro O, Naeije R, Sood N, Swerdlow PS, Hildesheim M, Gladwin MT; ASSET study group*.

Br J Haematol. 2010 May;149(3):426-35. doi: 10.1111/j.1365-2141.2010.08097.x. Epub 2010 Feb 17.

16.

Climatic and geographic temporal patterns of pain in the Multicenter Study of Hydroxyurea.

Smith WR, Bauserman RL, Ballas SK, McCarthy WF, Steinberg MH, Swerdlow PS, Waclawiw MA, Barton BA; Multicenter Study of Hydroxyurea in Sickle Cell Anemia.

Pain. 2009 Nov;146(1-2):91-8. doi: 10.1016/j.pain.2009.07.008. Epub 2009 Aug 14.

PMID:
19683393
17.

Influence of plasma exchange on the disposition of the fourth generation cephalosporin cefepime.

Ibrahim RB, Liu CY, Cronin SM, Murphy BC, Cha R, Swerdlow P, Avila T, Smith ST, Lewis RA, Edwards DJ.

J Oncol Pharm Pract. 2009 Dec;15(4):217-22. doi: 10.1177/1078155209103103.

PMID:
19304881
18.

Zinc supplementation decreases oxidative stress, incidence of infection, and generation of inflammatory cytokines in sickle cell disease patients.

Bao B, Prasad AS, Beck FW, Snell D, Suneja A, Sarkar FH, Doshi N, Fitzgerald JT, Swerdlow P.

Transl Res. 2008 Aug;152(2):67-80. doi: 10.1016/j.trsl.2008.06.001. Epub 2008 Jul 11.

PMID:
18674741
19.

Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial.

Vichinsky E, Pakbaz Z, Onyekwere O, Porter J, Swerdlow P, Coates T, Lane P, Files B, Mueller BU, Coïc L, Forni GL, Fischer R, Marks P, Rofail D, Abetz L, Baladi JF.

Acta Haematol. 2008;119(3):133-41. doi: 10.1159/000125550. Epub 2008 Apr 11.

PMID:
18408362
20.

Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia.

Ataga KI, Smith WR, De Castro LM, Swerdlow P, Saunthararajah Y, Castro O, Vichinsky E, Kutlar A, Orringer EP, Rigdon GC, Stocker JW; ICA-17043-05 Investigators.

Blood. 2008 Apr 15;111(8):3991-7. doi: 10.1182/blood-2007-08-110098. Epub 2008 Jan 11.

Supplemental Content

Loading ...
Support Center